Organization | AO GENERIUM

AO GENERIUM Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Moscow Russian Federation (2009)

Organization Overview

First Clinical Trial

2017

NCT04601389

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

AO GENERIUM

Active Ingredients

Drugs in Phase 3 Trials (11)

budesonide (rhinocort) (1 trial)

C1 Esterase Inhibitor (Human) (Cinryze) (1 trial)

dornase alfa (pulmozyme) (2 trials)

eculizumab (Soliris) (2 trials)

formoterol (foradil) (1 trial)

gnr-038 (2 trials)

gnr-055 (2 trials)

omalizumab (xolair) (2 trials)

ranibizumab (lucentis) (1 trial)

romiplostim (nplate) (2 trials)

tenecteplase (tnkase) (1 trial)

Drugs in Phase 2 Trials (1)

gnr-084 (1 trial)

Drugs in Phase 1 Trials (1)

gnr-051 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Angioedema (Phase 1)

Angioedemas, Hereditary (Phase 1)

Asthma (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Coronavirus Infections (Phase 3)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Hemoglobinuria (Phase 3)

Hemoglobinuria, Paroxysmal (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Melanoma (Phase 1)

Metabolic Diseases (Phase 1)

Mucopolysaccharidoses (Phase 1)

Mucopolysaccharidosis II (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial APIs: 13